Business Context and Reporting Period
RF Acquisition Corp III (RFAC III), a Cayman Islands exempted company, filed this Form 8-K on July 9, 2026, to report the entry into a Material Definitive Agreement. The filing announces a proposed Business Combination with HCC Healthcare Pte. Ltd., a Singapore private company. The transaction involves a recapitalization of HCC Healthcare followed by a merger with a wholly-owned subsidiary of HCC Healthcare.
Key Financial Metrics and Transaction Terms
- Valuation: HCC Healthcare is valued at $500,000,000 on a fully-diluted basis.
- Share Price: Post-recapitalization, each Company Ordinary Share is valued at $10.00.
- Consideration:
- RFAC III ordinary shares will convert one-for-one into HCC Healthcare ordinary shares.
- RFAC III rights will be exchanged for one-tenth (1/10th) of one HCC Healthcare ordinary share.
- Financial Performance: The filing text does not provide specific revenue, profit, cash flow, or margin figures for either entity. It notes that HCC Healthcare has a history of losses.
- Liquidity and Debt: Specific debt levels and liquidity positions are not disclosed in this summary text, though the transaction is subject to the amount of funds available in the RFAC III trust account.
Material Changes and Transaction Structure
The primary material change is the execution of the Business Combination Agreement. The transaction structure includes:
- Recapitalization: HCC Healthcare will effect a recapitalization immediately prior to closing to align share value at $10.00 per share.
- Merger: RFAC III will merge with and into HCC Merger Sub Limited, with the surviving entity becoming a subsidiary of HCC Healthcare.
- Board Composition: The post-closing board of HCC Healthcare will comprise seven directors: six designated by HCC Healthcare and one by the Founder (Alfa 30 Limited).
Guidance, Risks, and Conditions
Conditions to Closing: The transaction is subject to several conditions, including the effectiveness of a Registration Statement, shareholder approval from both RFAC III and HCC Healthcare, listing approval on Nasdaq or NYSE, and the absence of a material adverse effect.
Termination Rights: The agreement may be terminated under customary circumstances, including failure to obtain shareholder approval, legal prohibitions, or if the closing does not occur within 270 days of the agreement date (unless RFAC III is in material breach).
Risks and Contingencies:
- Forward-Looking Statements: The filing contains numerous forward-looking statements regarding future results, which are subject to risks and uncertainties.
- Profitability: HCC Healthcare has a history of losses, and there is a risk it may not achieve profitability.
- Redemptions: The amount of redemption requests by RFAC III shareholders could impact the funds available for the transaction.
- Regulatory and Operational Risks: Risks include regulatory approvals, foreign ownership restrictions, currency fluctuations, and the ability to retain key employees.
Investor Verification Checklist
- Verify the final valuation and share exchange ratio in the definitive proxy statement/prospectus (Form F-4).
- Confirm the amount of cash remaining in the RFAC III trust account after potential shareholder redemptions.
- Review HCC Healthcare's audited financial statements to assess the extent of its history of losses and path to profitability.
- Monitor the status of regulatory approvals and the effectiveness of the Registration Statement.
- Check for any updates on the listing approval status on Nasdaq or the NYSE.